GV has contributed to a series B round for Evox Therapeutics, a spinout of University of Oxford whose existing shareholders include Oxford Sciences Innovation.
UK-based exosome therapeutics developer Evox Therapeutics closed a £35.5m ($45.4m) series B round today backed by GV, the corporate venturing arm of diversified conglomerate Alphabet.
Redmile Group led the round, which also featured University of Oxford and its patient capital fund, Oxford Sciences Innovation (OSI), as well as Panacea Healthcare Ventures, Borealis Ventures, Cowen Healthcare Investments and assorted angel investors.
Spun out of University of Oxford in 2016, Evox Therapeutics is developing drugs for rare, life-threatening conditions with a high…
